Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisRoivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis GlobeNewswire
||
Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK,... 
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study EnrollmentElicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment GlobeNewswire
||
Phase 2 randomized study of ELI-002 enrolled 135 patients; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics,... 
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register NowPresenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now GlobeNewswire
||
MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) — EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5,... 
Ero Copper Announces Updated Mineral Reserve and Resource Estimates for the Xavantina OperationsEro Copper Announces Updated Mineral Reserve and Resource Estimates for the Xavantina Operations GlobeNewswire
||
VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to announce an update of its National... 
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid LeukemiaTerns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia GlobeNewswire
||
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment... 
Rehmann Foundation Grants $100,000 to Support Local OrganizationsRehmann Foundation Grants $100,000 to Support Local Organizations GlobeNewswire
||
TROY, Mich., Dec. 03, 2024 (GLOBE NEWSWIRE) — The nonprofit Rehmann Foundation today announced that it has awarded $100,000 in grants to nine outstanding organizations in Michigan, Ohio, and... 
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. GlobeNewswire
||
– Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor – – Proceeds to fund development... 
Keros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptKeros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept GlobeNewswire
||
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered... 
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisKinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis GlobeNewswire
||
Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK,... 
G-III Apparel Group Announces Date for Third Quarter 2025 ResultsG-III Apparel Group Announces Date for Third Quarter 2025 Results GlobeNewswire
||
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) — G-III Apparel Group, Ltd. (NASDAQ: GIII) a global fashion leader with expertise in design, sourcing, and marketing, today announced that it...